GLP1R and fatty liver disease: In both patients and mice with NAFLD, there is a marked reduction in hepatic GLP-1 and GLP-1R expression; however, exogenous butyrate supplementation not only reverses this trend but also modulates blood glucose metabolism and reduces hepatic steatosis and inflammation (Chen and Vitetta, 2020).